Recognizing and Managing a Rheumatoid Arthritis Flare: A Comprehensive Step-by-Step Action Plan

Authors: Dr. Sakti Jyoti Biswas
Recognizing and Managing a Rheumatoid Arthritis Flare: A Comprehensive Step-by-Step Action Plan
DOI
10.25125/imjh-sep-2026-1
DIN
IMJH-SEP-2026-1
Abstract

Rheumatoid arthritis (RA) is a systemic, chronic autoimmune disease defined by progressive synovial inflammation, structural joint damage, and widespread systemic complications. Despite significant advances in targeted synthetic and biological disease-modifying antirheumatic drugs (DMARDs), patients frequently experience acute exacerbations of disease activity known as flares. These periods of intensified pain, joint swelling, morning stiffness, and systemic fatigue significantly impair functional capacity, reduce health-related quality of life, and contribute to long-term radiographic joint damage if left unmanaged. This paper provides an evidence-based clinical analysis of the recognition, pathobiological mechanisms, and structured management of RA flares. It proposes a six-step action plan integrating validated disease activity metrics, biomarker monitoring, patient-reported outcome measures (PROMs), pharmacological escalation protocols, non-pharmacological therapies, and self-management strategies. By standardizing flare recognition and clinical response, healthcare providers can mitigate structural damage, optimize patient autonomy, and improve long-term disease outcomes.

Keywords
Rheumatoid arthritis flare DAS28 CDAI disease activity Inflammatory synovitis Corticosteroid bridging therapy DMARD optimization Treat-to-Target (T2T) strategy.
Download Options
Download Full PDF
Share Article
Facebook Twitter LinkedIn
Introduction

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent inflammation of the synovial membrane (synovitis), leading to cartilage degradation, bone erosions, and systemic extra-articular manifestations [1]. While modern therapeutic paradigms—specifically the "Treat-to-Target" (T2T) approach—have made sustained clinical remission (DAS28<2.6) or low disease activity (DAS28≤3.2) achievable goals, the natural history of RA remains intrinsically episodic [2]. Patients frequently experience acute, unpredictable spikes in disease activity termed "flares."

Flares represent more than temporary discomfort. Uncontrolled disease exacerbations accelerate joint erosion, elevate cardiovascular risk via systemic inflammatory pathways, and cause severe physical disability [3]. Beyond structural and systemic damage, flares inflict a major psychological toll. The unpredictability of flare onset creates anticipatory anxiety, disrupts occupational productivity, and exacerbates illness perception, leading to functional helplessness [4].

Historically, clinical trial endpoints focused primarily on static measures of disease activity at discrete visits, often overlooking the dynamic, transient nature of flares. However, research led by the Outcome Measures in Rheumatology (OMERACT) RA Flare Working Group has established flares as critical primary outcomes in clinical trial design and everyday clinical practice [5].

Despite this recognition, translating flare identification into structured clinical intervention remains challenging. Patients often struggle to distinguish an inflammatory flare from non-inflammatory musculoskeletal pain, such as secondary osteoarthritis or fibromyalgia, leading to either delayed medical presentation or unnecessary escalation of immunosuppressive therapy [6]. Conversely, busy clinical practices may lack formal protocols to rapidly triage and manage patient-reported exacerbations.

This article outlines a comprehensive, step-by-step action plan for recognizing and managing RA flares. Integrating immunologic concepts, clinical assessment tools, pharmacological protocols, and non-pharmacological strategies, this blueprint aims to bridge the gap between patient experience and clinical decision-making.

Medical Journal IMJ Health Call for Papers

Conclusion

Managing rheumatoid arthritis flares effectively is essential for preventing structural joint damage, preserving functional independence, and maintaining quality of life. Modern rheumatology has advanced beyond treating flares with ad-hoc corticosteroid bursts. Optimal outcomes require a structured, evidence-based approach that combines validated disease metrics, clinical evaluation, targeted pharmacological escalation, and non-pharmacological therapies.

By implementing this step-by-step action plan, clinicians and patients can work together to systematically recognize, triage, and manage acute exacerbations. Differentiating true inflammatory flares from infectious mimics or central pain sensitization ensures that immunosuppressive adjustments are applied safely and effectively. Equipping patients with self-assessment tools, clear protocols, and non-pharmacological coping strategies restores autonomy, reduces anxiety, and supports long-term disease control.

References
  1. Alivernini, S., MacDonald, L., Elmesmari, A., Finlay, S., Tolusso, B., Gigante, M. R., et al. (2020). Distinct synovial macrophage subsets drive remission and relapse in rheumatoid arthritis. Nature Medicine, *26*(8), 1295-1306.
  2. Aletaha, D., & Smolen, J. S. (2005). The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in clinical practice and research. Rheumatic Disease Clinics of North America, *31*(4), 773-786.
  3. Alten, R., Christensen, R., Bingham III, C. O., Almeida, C., Hewlett, S., Kirwan, J., et al. (2011). Measurement of rheumatoid arthritis flares: The OMERACT RA Flare Questionnaire (RA-FQ). Journal of Rheumatology, *38*(8), 1745-1752.
  4. Brosseau, L., Yonge, K. A., Robinson, V., Marchand, S., Judd, M., Wells, G. A., et al. (2003). Thermotherapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews, (4), CD002826.
  5. Bykerk, V. P., Shadick, N., Frits, M. L., Bingham III, C. O., Iannaccone, C. K., Glass, R. J., et al. (2014). Flares in rheumatoid arthritis: Frequency and association with 2-year radiographic progression. Arthritis Care & Research, *66*(1), 38-46.
  6. Flurey, C. A., Morris, M., Richards, P., Hughes, R., & Hewlett, S. (2014). It's localized, it's generalized, it's severe: How patients perceive the onset of rheumatoid arthritis flares. Musculoskeletal Care, *12*(4), 227-236.
  7. Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., et al. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, *73*(7), 1108-1123.
  8. Garip, Y., Eser, F., Bodur, H., & Yilmaz, O. (2011). Sleep quality in rheumatoid arthritis: Relationship with disease activity, fatigue, depression, and functional status. Rheumatology International, *31*(11), 1453-1456.
  9. Gartlehner, G., Patel, S. V., Feltner, C., Weber, R. P., Long, R., Mullican, K., et al. (2021). Defining and measuring flares in rheumatoid arthritis: A systematic review for OMERACT. Annals of the Rheumatic Diseases, *80*(6), 712-721.
  10. Haschka, J., Englbrecht, M., Hueber, A. J., Hayer, S., Englert, S., Simon, D., et al. (2016). Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: Interim results of the RETRO study. Annals of the Rheumatic Diseases, *75*(1), 45-51.
  11. Matcham, F., Rayner, L., Steer, S., & Hotopf, M. (2016). The association between depression and disease activity in rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology, *55*(12), 2136-2148.
  12. McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, *365*(23), 2205-2219.
  13. Meeus, M., Vervisch, S., De Clerck, L. S., Moorkens, G., Hans, G., & Nijs, J. (2012). Central sensitization in patients with rheumatoid arthritis: A systematic review. Seminars in Arthritis and Rheumatism, *41*(4), 556-567.
  14. Nygaard, G., & Firestein, G. S. (2020). Restoring joint homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nature Reviews Rheumatology, *16*(6), 316-333.
  15. Pincus, T., Swearingen, C. J., & Yazici, Y. (2008). RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Validity and reliability. Journal of Rheumatology, *35*(11), 2136-2143.
  16. Schiff, M. H., Jaffe, J. S., & Freundlich, B. (2014). Head-to-head clinical trial of subcutaneous methotrexate versus oral methotrexate in rheumatoid arthritis. Annals of the Rheumatic Diseases, *73*(6), 1049-1054.
  17. Smolen, J. S., Aletaha, D., & McInnes, I. B. (2018). Rheumatoid arthritis. Lancet, *392*(10147), 615-628.
  18. Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., et al. (2003). A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology, *42*(2), 244-257.
  19. Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., et al. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, *79*(6), 685-699.
  20. Straub, R. H., & Cutolo, M. (2018). Psychoneuroimmunology–inflammatory mechanisms in rheumatoid arthritis. Nature Reviews Rheumatology, *14*(10), 603-616.
  21. Strehl, C., Bijlsma, J. W., de Wit, M., Boers, M., Caeyers, N., Cutolo, M., et al. (2016). Defining conditions where long-term glucocorticoid treatment has an acceptable low-risk profile in rheumatoid arthritis. Annals of the Rheumatic Diseases, *75*(6), 952-957.
  22. van der Heijde, D. M., van 't Hof, M. A., van Riel, P. L., Theunisse, L. A., Lubberts, E. W., van Leeuwen, M. A., et al. (1990). Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Annals of the Rheumatic Diseases, *49*(11), 916-920.
  23. Vriezekolk, J. E., Geenen, R., Hartkamp, A., Godaert, G. L., van Booma, A., & Bijlsma, J. W. (2012). Psychological variables associated with pain and fatigue in rheumatoid arthritis: A structural equation modeling approach. Journal of Psychosomatic Research, *73*(5), 376-382.
Article Preview
Quick Actions
Download PDF View References
Article Info
Pages
01-13